Company intelligence / Profile preview

Changchun Haiyue Pharmaceutical

Changchun, Jilin Sheng, Chinadnb.com ↗

Ownership: Private
Development stage: Other

Overview

Changchun Haiyue Pharmaceutical has commercialized at least one drug—esomeprazole magnesium/sodium bicarbonate—for duodenal ulcer in China since September 2022. The company also develops or licenses drugs targeting proton pumps and PPARα, with some products approved outside China via partnerships. Its pipeline includes several small molecule drugs across digestive, metabolic, oncology, infectious disease, and ENT indications.

Therapeutic areas: Infectious DiseasesGastroenterologyEndocrinologyOncologyOtherCardiovascular
Modalities: Small moleculeProton pump inhibitor (as a class of small molecules)PPARα agonist (as a class of small molecules)
Industry: Biotech

Partnerships

Hanmi Pharmaceutical Co., Ltd. for fenofibric acid licensing/distribution

Beyond the preview

Go deeper on Changchun Haiyue Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Changchun Haiyue Pharmaceutical.

Explore the full profile